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SUMMARY
Introduction Accurate diagnosis of chronic lymphocytic leukemia (CLL) acquires immunophenotyp-
ing by flow cytometry in order to facilitate differential diagnosis between CLL and other mature B-cell 
neoplasms (MBCN).
Objective The aim of this study was to define immunological profile of CLL cells.
Methods Immunophenotyping by flow cytometry was performed on peripheral blood specimens at 
diagnosis in the group of 211 patients with de novo MBCN.
Results Absolute count of B-cells was significantly increased in all MBCN patients comparing to healthy 
control group (p<0.05). B-cell monoclonality was detected in 96% of all MBCN patients, by using surface 
immunoglobulin (sIg) light chain restriction. B-cell antigens, CD19, CD20, CD22, were expressed with very 
high frequency in CLL and other MBCN. In comparison with other MBCN, in CLL group, the frequency 
of expression was higher for CD5 and CD23 (p<0.0001), though lower for FMC7 antigen (p<0.0001). CLL 
patients were characterized by lower expression patterns of CD20, CD22, CD79b, and sIg (p<0.0001) as 
well as higher expression pattern of CD5 antigen (p<0.05). Correlation between the final diagnosis of 
MBCN and values of CLL scoring system showed that the majority of CLL patients (97%) had higher values 
(5 or 4) whereas the majority of other MBCN patients (96%) had lower score values (0-3).
Conclusion Our results have shown that characteristic immunophenotype which differentiates CLL from 
other MBCN is defined by following marker combination - CD19+ CD20+low CD22+low CD5+high CD23+ FMC7- 
CD79b+low sIg+low. CLL score values of 5 or 4 points are highly suggestive for diagnosis of CLL.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a clonal 
B-cell neoplasm of mature cells whose diagno-
sis is based on clinical manifestations, cell mor-
phology and immunophenotyping [1, 2, 3]. Fur-
thermore, absolute count of monoclonal B-cells, 
demonstrated by immunophenotyping and flow 
cytometry, should be ≥ 5000 cells/μl, suggesting 
the diagnosis of B-cell disorder [1, 2].
The most reliable methodology for the di-
agnosis of CLL is immunophenotyping by flow 
cytometry (IFC) [4]. IFC is usually performed 
in all patients with lymphocytosis, in order to 
confirm the diagnosis of CLL, suspected by 
morphology and clinical data. Application of 
immunological markers primary determines B-
cells by showing surface immunoglobulin (sIg) 
light chain restriction [5]. It is also known that 
there is no single marker exclusively expressed 
on CLL cells, but a composite immunophe-
notype which integrates many different B-cell 
markers and helps distinguishing CLL from 
other mature B-cell neoplasms (MBCN). The 
expression profile of these leukocyte antigens is 
included in the specialized CLL scoring system 
[6, 7], that was created in order to distinguish 
typical CLL (4-5 points) from other MBCN (0-3 
points) (Table 1). It has also been suggested that 
CLL cells have immunophenotypic signature 
similar to that of activated follicular marginal 
zone B1 cell, which normally express CD5, and 
coexpress membrane IgM and IgD [8].
Distinguishing CLL from other MBCN, 
based only on cytomorphology and clinical 
presentation, may be difficult. Considering 
the mature B-cell leukemias, CLL needs to be 
distinguished from prolymphocytic leukemia 
(PLL) and hairy cell leukemia (HCL), while in 
the case of B-cell non-Hodgkin lymphomas (B-
NHL) in leukemic phase, problems of differ-
ential diagnosis arise between CLL and mantle 
cell lymphoma (MCL), splenic marginal zone 
lymphoma without/with villous lymphocytes 
(SMZL/SLVL) and follicular lymphoma (FL) 
[5]. The precise distinction of CLL from these 
related diseases is important in terms of the ac-
curate diagnosis, prognosis and adequate treat-
ment of patients.
OBJECTIVE
The aim of this single center retrospective study 
was to determine the value of each explored 
membrane leukocyte antigen in differential 
diagnosis of CLL from other MBCN, and to 
define immunological profile of CLL.  
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METHODS
Patients
We analyzed 211 consecutive untreated patients (pts) with 
suspected diagnosis of de novo MBCN, referred for stand-
ard diagnosis to the Laboratory for immunophenotyping 
and flow cytometry, Clinic of Hematology, Clinical Center 
of Serbia, in the time period November 2002- October 
2005. Final diagnosis of CLL was confirmed in 183 pa-
tients. The diagnosis of other MBCN was confirmed in 28 
patients with the following diagnosis: MCL (8 pts), SMZL 
(8 pts), FL (4 pts), lymphoplasmocytic lymphoma (2 pts), 
B-NHL, not otherwise specified (5 pts), and HCL (1 pt). 
Diagnosis was established according to the standard crite-
ria [2, 4]. Other than immunophenotypic characteristics, 
demographic (sex and age) and hematological data (he-
moglobin, platelet count, leukocyte count, percentage of 
lymphocytes in peripheral blood and bone marrow) were 
analyzed. This study also included peripheral blood speci-
mens of 20 healthy volunteers as a control group. 
Flow cytometric immunophenotyping
Immunophenotyping was performed by using direct im-
munofluorescent technique and flow cytometry [9] on pe-
ripheral blood specimens anticoagulated by heparin (40 
I.U./ml; 5000 I.U./ml, ICN Galenika). Mononuclear cells 
were isolated by density gradient centrifugation (Histo-
paque-1077, SIGMA-ALDRRICH, USA) and washed two 
times with 10ml of 2% of fetal calf serum in phosphate 
buffered saline (FCS/PBS), pH 7.4. Cell concentration was 
adjusted to 10∙106/ml, and 100 μl aliquots of cell suspen-
sion were stained with optimal concentrations of commer-
cial monoclonal antibodies (BD Biosciences, USA) organ-
ized in two-color panels: CD2-FITC (clone S5.2), CD3-
PE (clone SK7), CD5-PE (clone UCHT2; clone L17F12), 
CD10-PE (clone HI10a), CD19-PE (clone 4G7), CD20-
FITC (clone L27), CD22-PE (clone S-HCL-1), CD23-PE 
(clone EBVCS-5), CD38-FITC (clone HIT2; clone HB7), 
CD79b-PE (clone CB3.1), CD103-PE (clone Ber-ACT8), 
FMC7-FITC (clone FMC7), anti-κ-FITC (polyclonal), 
anti-λ-FITC (polyclonal). After incubation for 20 min-
utes at +4oC in the dark, cells were washed with 2ml of 
2% FCS/PBS, pH 7.4 solution and fixed with 0.5ml of 1% 
paraformaldehyde/PBS, pH 7.4 solution. The flow cyto-
metric analysis was performed on a FACSCalibur (BD Bio-
sciences, USA), using the software CellQuest Pro (version 
4.0.2). Analysis was performed on lymphocyte population 
gated according to forward and side scatter characteristics 
(FSC/SSC). A minimum of 10,000 gated events was ac-
quired for each aliquot per tube. The results were given as 
a percentage of lymphocytes reactive with antibodies. An 
antigen was considered positive when at least 30% of gated 
lymphocytes expressed explored antigen above the isotypic 
control [6]. The patterns of antigen expression were esti-
mated according to the relative position of a peak of fluo-
rescent emission on the log scale in the fluorescence axis 
as follows: low (Ag+low), medium (Ag+medium), high (Ag+high) 
expression [6] (Figure 1). Detection of the monoclonal B-
cell population in the peripheral blood was done according 
to overall sIgκ:sIgλ ratio (>3 for sIgκ monoclonality or <0.3 
for sIgλ monoclonality) [10].
Absolute counts of peripheral blood B-cells and T-cells 
were calculated by using double platform methodology 
[11]. Proportions of peripheral blood B-cells (percent-
age of CD19+ cells/ lymphocytes) and T-cells (percentage 
of CD3+ cells/lymphocytes), detected by flow cytometry, 
were combined with the absolute leukocyte count and lym-
phocyte differential.
Statistics
Statistical analyses were performed using the Statistica® 
(version 7.1, StatSoft®, Inc. Tulsa USA, 2005) licensed sta-
Table 1. Scoring system for the differential diagnosis of chronic 
lymphocytic leukemia (CLL) [5]
Marker
Points
1 0
CD5 Positive Negative
CD23 Positive Negative
FMC7 Negative Positive
sIg Low Medium/high
CD22/CD79b Low/negative Medium/high
sIg – surface membrane immunoglobulin
Figure 1. The patterns of antigen (Ag) expression were estimated according to the relative peak position of phycoerythrin (PE) fluorescent 
emission on the log scale in the fluorescence axis, as follows: a) low (Ag+low), when the peak of fluorescent emission was within the first log 
percentile; b) medium (Ag+medium), when the peak of fluorescent emission was within the second log percentile; c) high (Ag+high), when the peak 
of fluorescent emission was within or more than three log percentiles.     
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tistical analysis software package. Data were expressed as 
mean and median values and interquartile range. Compar-
ison between the groups was performed using Chi-square 
test and Student’s t-test. Statistical significance was defined 
as p value <0.05.
RESULTS
Patient characteristics
The main demographic and hematological characteristics 
of CLL and other MBCN patients were shown in Table 2. 
Population of males dominated in both groups with the 
mean age of 62 years. For the most of studied character-
istics no significant differences between CLL and other 
MBCN patient groups were found. The only significant 
difference was established regarding the values of hemo-
globin and platelets. The patients with CLL had signifi-
cantly higher mean values of hemoglobin and platelets in 
comparison to other MBCN patients (p<0.05). At pres-
entation, anemia (Hb<110 g/L) was present in 16% and 
thrombocytopenia (Tr<100×109/L) in 6% of CLL patients.
Peripheral blood B-cell counting
Detection and estimation of peripheral blood B-cell and 
T-cell populations were performed by IFC in the whole 
MBCN patient group. The analysis of relative distribution 
of B-cells and T-cells in lymphocyte population showed 
significantly higher mean proportion of B-cells (82% vs. 
7.5%) as well as significantly lower mean proportion of 
T-cells (13% vs. 75%), compared to the healthy controls 
(p<0.05). Besides, the mean absolute count of peripheral 
blood B-cells in the MBCN group was significantly higher 
compared to the healthy control group (42267 vs. 196 cells/
µl) (p<0.05). It was also found that the vast majority of CLL 
patients (95%) had absolute count of peripheral B-cells 
above 5000 cells/µl.
Immunophenotypic characteristics of MBCN patients
To define immunological diagnosis, immunophenotyping 
data for each patient with MBCN were analyzed regarding 
CLL scoring system by calculating score value [5]. The 
patients were divided into two groups according to im-
munological diagnosis: immuno dg CLL (score 5 and 4) 
(180/211 pts) and immuno dg non-CLL (score ≤3) (31/211 
pts). Basic immunophenotypic characteristics of these 
groups were shown in Tables 3 and 4.
It was recorded that CD19 antigen was expressed in all 
analyzed MBCN patients. Considering differences in anti-
gens expression between the groups of patients with differ-
ent immuno diagnosis, it was found that CD5 antigen was 
expressed with higher frequency in CLL group comparing 
to non-CLL group (99% vs. 74%, p<0.0001). The similar 
result was found for CD23 antigen, where it was expressed 
in majority of CLL comparing to non-CLL (98% vs. 32%, 
p<0.0001) patients. The analysis of expression patterns of 
CD5 antigen revealed that pattern CD5+high predominated 
in the CLL group (p=0.0489). In case of CD23 antigen, CLL 
group was characterized by predomination of higher ex-
pression patterns (CD23+medium and CD23+high) comparing to 
non-CLL group characterized mainly with CD23+low expres-
sion pattern (p>0.05). Regarding FMC7 antigen expression, 
we found very low frequency of expression in CLL group 
comparing to non-CLL group (8% vs. 100%, p<0.0001).
Expression of CD20 and CD22 antigens was detected 
with very high frequency in CLL group (99% and 94%, 
Table 2. Demographic and hematological characteristics of MBCN 
patients
Characteristics
Groups of patients
p value MBCN
(N=211)
CLL
(N=183)
Other 
MBCN
(N=28)
Sex (n)
Male 147 127 19
NS Female 64 56 9
Ratio 2.3/1 2.3/1 2.1/1
Age (years)
Mean±SD 62±11 62±11 62±10
NS Median 64 64 63
Range 32–83 32–83 37–75
Hemoglobin 
(g/l)
Mean±SD 127±21 129±19 112±25
0.0001 Median 130 132 118
Range 54–160 61–160 54–147
Platelets 
(×109/l)
Mean±SD 197±97 207±94 137±100
0.0005 Median 185 197 103
Range 3–751 3–751 15–455
WBC count 
(×109/l)
Mean±SD 61±93 61±96 63±74
NS Median 34 35 25
Range 5–910 6–910 5–350
Peripheral 
blood Ly (%)
Mean±SD 77±13 77±12 77±15
NS Median 80 79 83
Range 39–100 39–100 49–100
Bone marrow 
Ly (%)
Mean±SD 65±22 64±22 75±19
NS Median 72 70 79
Range 5–98 5–98 28–96
n – number of patients with the specific characteristics; WBC – white blood cells; 
Ly – lymphocytes; MBCN – mature B-cell neoplasm; N – total number of the 
analyzed patients; CLL – chronic lymphocytic leukemia; p value – CLL vs. other 
MBCN; NS – not significant
Table 3. The frequency of antigen expression in MBCN patients, group 
with CLL (score 4-5) and non-CLL (score ≤3)
Antigen
% (n/N)
p value
MBCN CLL  
(score 4-5)
Non-CLL 
(score ≤3)
CD19 100 (211/211) 100 (180/180) 100 (31/31) /
CD5 95 (201/211) 99 (178/180) 74 (23/31) <0.0001
CD23 88 (186/211) 98 (176/180) 32 (10/31) <0.0001
FMC7 21 (45/211) 8 (14/180) 100 (31/31) <0.0001
CD20 99 (209/211) 99 (178/180) 100 (31/31) NS
CD22 95 (199/210) 94 (169/180) 100 (30/30) NS
CD79b 63 (103/163) 57 (80/139) 96 (23/24) 0.001
sIgκ 57 (120/211) 57 (103/180) 52 (16/31) NS
sIgλ 39 (83/211) 38 (68/180) 48 (15/31) NS
CD38 35 (63/182) 32 (50/156) 50 (13/26) NS
n – number of patients that are positive for the analyzed antigen; N – total 
number of the analyzed patients; p value – CLL vs. non-CLL  
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respectively) as well as in all patients of non-CLL group. 
The analysis of their expression patterns showed that the 
majority of CLL patients had CD20+low and CD22+low ex-
pression patterns (70% and 74%, respectively) compared 
to non-CLL patients where predominated higher expres-
sion patterns CD20+high and CD22+med/high (100% and 77%, 
respectively) (p<0.0001).
The analysis of the component of B-cell receptor CD79b 
revealed that it was expressed with lower frequency in CLL 
group compared to non-CLL group (57% vs. 96%, p=0.001) 
whereas CD79b+low expression pattern was detected in the 
majority of CLL patients compared to non-CLL ones (99% 
vs. 30%, p<0.0001).
Monoclonality of B-cell population, defined according 
to the presence of sIg light chain restriction, was detected 
in 95% of CLL patients as well as in all non-CLL patients. 
Frequency of sIgκ+ was higher than sIgλ+ cases, in both 
analyzed groups. The analysis of sIg expression patterns 
demonstrated that the majority of CLL patients had sIg+low 
expression pattern compared to non-CLL patients (97% vs. 
22%) (p<0.0001).
Prognostic marker CD38 was expressed with lower 
frequency in CLL group comparing to non-CLL group of 
patients (32% vs. 50%, p>0.05).
Correlation of CLL score with final diagnosis of MBCN
The final diagnosis of MBCN was correlated with CLL 
score and the obtained results were shown in Graph 1. The 
great majority of CLL patients had score of 5 or 4 points 
(97%). CLL patients with score ≤3 points were distributed 
as follows: 3 points (2%), and 2 points (1%). There were 
no CLL patients with score of 1 or 0 points. In the group 
of other MBCN, the majority of patients (96%) had lower 
scores (≤3 points). Only 1 patient had score of 4 points and 
there were no patient with score of 5 points in the group 
of other MBCN.
DISCUSSION
Immunophenotyping by flow cytometry is essential for 
the diagnosis and subclassification of MBCN, particularly 
CLL [1, 5]. Because the clinical evolution and response to 
treatment differ between CLL and other MBCN, an ac-
curate diagnosis is very important. Although CLL has a 
relatively specific immunophenotypic profile comparing 
to other MBCN, there is some overlapping regarding the 
expression of membrane markers. The CLL scoring system 
was created in order to make distinction between CLL and 
other MBCN entities easier [6, 7].
 This study retrospectively analyzed immunophenotypic 
features of 211 patients with de novo MBCN, including 183 
patients with final diagnosis of CLL and 28 patients with 
other MBCN. The CLL patients at presentation usually 
showed typical clinical and hematological characteristics, 
including the presence of anemia and/or thrombocyto-
penia in low frequency (16% vs. 6%, respectively). It was 
also found that patients with CLL had significantly higher 
mean values of hemoglobin and platelets in comparison 
with other MBCN patients, which was in correlation with 
literature data [3].
Detection and counting of peripheral blood B-cell pop-
ulation in patients with MBCN, based on CD19 antigen 
expression, as well as exploring of clonality status of B-cell 
populations, based on sIg light chain restriction, repre-
sent very important information provided by IFC [2]. All 
patients with MBCN had significantly increased circulat-
ing B-cells at presentation whereas monoclonal status was 
detected in high frequency (96%). Moreover, it was found 
that the great majority of CLL patients (95%) had abso-
lute count of monoclonal peripheral blood B cells above 
Table 4. The frequency of the antigen expression patterns in group 
with CLL (score 4-5) and non-CLL (score ≤3)
Pattern of antigen 
expression
% (n/N)
p value CLL  
(score 4-5)
Non-CLL  
(score ≤3)
CD20
Low 70 (124/178) 0 (0/31)
<0.0001 Medium 21 (37/178) 0 (0/31)
High 9 (17/178) 100 (31/31)
CD22
Low 74 (125/168) 23 (7/30)
<0.0001 Medium 21 (36/168) 20 (6/30)
High 4 (7/168) 57 (17/30)
CD79b
Low 99 (79/80) 30 (7/23)
<0.0001 Medium 1 (1/80) 30 (7/23)
High 0 (0/80) 40 (9/23)
sIg
Low 97 (165/171) 22 (7/32)
<0.0001 Medium 2 (4/171) 41 (13/32)
High 1 (2/171) 37 (12/32)
CD5
Low 12 (12/104) 30 (6/20)
0.049 Medium 23 (24/104) 30 (6/20)
High 65 (68/104) 40 (8/20)
CD23
Low 42 (74/176) 90 (9/10)
NS Medium 31 (54/176) 10 (1/10)
High 27 (48/176) 0 (0/10)
FMC7
Low 93 (13/14) 61 (19/31)
NS Medium 7 (1/14) 39 (12/31)
High 0 (0/14) 0 (0/31)
n – number of patients that exhibit specific pattern of the antigen expression; 
N – total number of the analyzed patients; p value – CLL vs. non-CLL
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Graph 1. Comparison of frequency of the chronic lymphocytic leuke-
mia (CLL) score points in patients with the final diagnosis of CLL and 
other mature B-cell neoplasms (MBCN)
p<0.0001     
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5000 cells/µl. Detection of the increased absolute count of 
monoclonal peripheral blood B-cells in patients with nor-
mal WBC count could be important for early differential 
diagnosis of MBCN [2].
To estimate the value of each membrane leukocyte an-
tigen in differential diagnosis of CLL, the expression of 
three B-cell lineage antigens (CD19, CD20, CD22), and 
five antigens from the CLL scoring system (CD5, CD23, 
FMC7, CD79b, sIg), including prognostic antigen CD38 
was analyzed. Among lineage B-cell antigens, CD19 was 
expressed in all our patients with MBCN, indicating that 
it is the only marker consistently expressed on leukemic B-
cells. Our results are in the line with literature data which 
select CD19 as one of the best gating antigen for immu-
nophenotypic analysis of B cell neoplasms, including CLL 
[12]. However, other two lineage B-cell antigens, CD20 
and CD22, were less consistently expressed on CLL cells. 
The probable reason for that is their low expression levels 
on CLL cells. In contrast, in other MBCN, all patients ex-
pressed CD20 and CD22 at higher expression levels. Ac-
cording to our results, CD20 and CD22 were not important 
for differential diagnosis of CLL, because these antigens 
were expressed in virtually all our MBCN cases. Our re-
sults are in the line with results obtained by Delgado et 
al. [13]. On the other hand, the assessment of the CD20 
expression in CLL patients by IFC would be of the utmost 
clinical importance if the anti-CD20 immunotherapy was 
considered [14].
One of antigens from CLL scoring system is CD5, which 
is generally considered as pan T-cell antigen, although 
some restricted B cells, named B1 cells, also express CD5 
[15]. In pathological conditions, CD5 is usually expressed 
in CLL and MCL, in some cases of PLL, diffuse large B-
cell lymphoma and HCL [1]. Our results showed that fre-
quency of expression of CD5 antigen as well as CD5+high ex-
pression pattern was significantly higher in CLL compared 
to non-CLL group. Considering these data, CD5 antigen 
could have important role in differential diagnosis of CLL. 
Similar results were found in studies by Pangalis et al. and 
Deneys et al., where the frequency of CD5 expression in 
CLL was very high (90% vs. 98%) [16, 17].
Considering the CD23 antigen, it was shown that it was 
expressed in the majority of CLL compared to non-CLL 
patients, which made it relevant for differential diagno-
sis of CLL. Our results are in the line with literature data 
suggesting that CD23 antigen is one of the most impor-
tant markers for differential diagnosis between CLL and 
MCL [18]. Addressing this issue, DiRaimondo et al. dem-
onstrated that CLL/CD23- variant was rare (6%) and that 
the majority of MBCL patients with CD23-CD5+ cells had 
MCL [18]. In these cases, the diagnosis of MCL has to be 
confirmed by cyclin D1 immunostaining on biopsy and/or 
by detection of chromosomal translocation t(11;14).
FMC7 antigen is also considered to be reliable marker 
for differential diagnosis of CLL, distinguishing CLL from 
other MBCN [5]. Our results support this finding showing 
that only 8% of CLL patients expressed FMC7, whereas it 
was expressed in all patients from non-CLL group. Fur-
thermore, some studies have shown wide range of frequen-
cy of FMC7 positive CLL cases (12-30%) [13, 17].
CD79b is one of the B-cell receptor complex compo-
nents [15] and represents the latest antigen that was in-
corporated into CLL scoring system [7]. The largest series 
of CLL so far published has provided the evidence that the 
membrane expression of CD79b is greatly diminished or 
even absent in the majority of the typical CLL [19, 20]. In 
our CLL group, CD79b was expressed with lower frequen-
cy compared to non-CLL group (57% vs. 96%), whereas 
CD79b+low expression pattern was detected in the major-
ity of CLL patients, similar to the study by Garcia Vela et 
al. [20]. These characteristics make this antigen a good 
marker for differential diagnosis of CLL.
Another component of the B-cell receptor complex is sIg, 
which is used to determine monoclonality of B-cells by flow 
cytometry, defined according to the presence of sIg light 
chain restriction. Although the monoclonality was detected 
in 95% of our CLL patients, Ig light chains were undetectable 
at presentation in 5% of patients, representing an aberrant 
feature of CLL cells [2]. In our CLL group, the frequency 
of sIgκ+ was higher than sIgλ+ cases. Likewise, in the study 
by Matutes et al. [6], it was shown that sIg was expressed in 
92% of CLL cases with similar distribution of sIgκ+ and sIgλ+ 
positive cases. Our results showed that the majority of CLL 
patients had significantly higher frequency of sIg+low expres-
sion pattern compared to the non-CLL patients, what makes 
this antigen important for differential diagnosis of CLL.
Concerning CD38 antigen that regulates apoptosis and 
proliferation of B-cells [15], the frequency of expression was 
found to be low (32%) in our CLL patients. Similarly, the 
other studies reported lower frequency of CD38 antigen 
expression in CLL patients (20%-27%), where this antigen 
was presented exclusively as prognostic marker [21, 22, 23].
Based on our results, which determined the value of 
each explored antigen for differential diagnosis of CLL, 
we could define the specific immunophenotypic profile 
of CLL cells as follows: CD19+ CD20+low CD22+low CD5+high 
CD23+ FMC7- CD79b+low sIg+low (Figure 2). Moreover, it is 
of note that only the combination of the aforementioned 
Figure 2. Flow cytometry biparametric dot plots that illustrate specific immunophenotypic profile of the chronic lymphocytic leukemia (CLL) cells
FITC – fluorescein isothiocyanate; PE – phycoerythrin  
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antigens can be used for reliable differential diagnosis of 
CLL, distinguishing it from other MBCN.
By applying the CLL scoring system to all our patients 
with MBCN, it has been shown that the majority of pa-
tients with the final diagnosis of CLL (97%) had high score 
values (5 or 4). In contrast, a small group of our CLL pa-
tients had score value of 3 or 2 points (3%), indicating 
that CLL diagnosis would have to be reconsidered in these 
cases. Addressing this issue, the rate of CLL with score 3 
and 2 points was little higher (13%) in the study of Matutes 
et al. [6]. The majority of our patients with final diagno-
sis of non-CLL MBCN (96%) had lower score values (0 
- 3), whereas only one patient had score of 4 points (4%). 
Similarly in the study of Matutes et al. [6], the incidence of 
non-CLL MBCN with score 4 points was 0.5%. Our results 
confirmed that CLL score was very practical and useful in 
differential diagnosis of CLL.
CONCLUSION
Our results have shown that specific immunophenotype 
which differentiates CLL from other MBCN is defined 
with the following marker combination - CD19+ CD20+low 
CD22+low CD5+high CD23+ FMC7- CD79b+low sIg+low. This 
study has also shown that none of the explored antigens 
can separately discriminate CLL from other MBCN. It is 
only the combination of these antigens that makes possible 
to distinguish CLL from non-CLL MBCN. Furthermore, 
the CLL score value is of the utmost importance in the 
differential diagnosis of CLL based on the fact that the 
majority of CLL patients at presentation have score values 
of 5 or 4 points. Besides, all CLL patients at presentation 
have a significant increase of the circulating monoclonal 
B-cells, estimated by flow cytometry, which could be im-
portant for early diagnosis of disease.
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КРАТАК САДРЖАЈ
Увод За по  ста  вља  ње пре  ци  зне ди  јаг  но  зе хро  нич  не лим  фо-
цит  не ле  у  ке  ми  је (ХЛЛ) нео  п  ход  на је при  ме  на иму  но  фе  но  ти-
пи  за  ци  је про  точ  ном ци  то  ме  три  јом ра  ди по  у  зда  не ди  фе  рен-
ци  ја  ци  је од дру  гих зре  лих Б-ће  лиј  ских нео  пла  зми (ЗБЋН).
Циљ ра  да Глав  ни циљ овог ра  да је де  фи  ни  са  ње иму  но  фе-
но  тип  ског про  фи  ла ХЛЛ ће  ли  ја.
Ме  то  де ра  да Узор  ци пе  ри  фер  не кр  ви 211 бо  ле  сни  ка са 
ЗБЋН су ана  ли  зи  ра  ни при ди  јаг  но  стиковању бо  ле  сти при-
ме  ном иму  но  фе  но  ти  пи  за  ци  је и про  точ  не ци  то  ме  три  је.
Ре  зул  та  ти Про  сеч  на вред  ност ап  со  лут  ног бро  ја Б-лим  фо-
ци  та је би  ла ста  ти  стич  ки зна  чај  но по  ве  ћа  на у гру  пи бо  ле-
сни  ка са ЗБЋН у по  ре  ђе  њу с вред  но  шћу у кон  трол  ној гру  пи 
здра  вих ис  пи  та  ни  ка (p<0,05). Мо  но  кло  нал  ност Б-лим  фо  ци-
та је утвр  ђе  на код 96% бо  ле  сни  ка са ЗБЋН на осно  ву екс-
пре  си  је ла  ких ла  на  ца мем  бран  ских иму  но  гло  бу  ли  на (mIg). 
Б-ће  лиј  ски ан  ти  ге  ни CD19, CD20 и CD22 екс  при  ми  ра  ни су с 
ве  о  ма ви  со  ком уче  ста  ло  шћу код бо  ле  сни  ка са ХЛЛ, као и 
код бо  ле  сни  ка с оста  лим ЗБЋН. Код бо  ле  сни  ка са ХЛЛ уче-
ста  лост екс  пре  си  је CD5 и CD23 ан  ти  ге  на би  ла је ста  ти  стич  ки 
зна  чај  но ви  ша (p<0,0001), док је уче  ста  лост екс  пре  си  је FMC7 
ан  ти  ге  на би  ла ста  ти  стич  ки зна  чај  но ни  жа (p<0,0001), у од  но-
су на бо  ле  сни  ке с оста  лим ЗБЋН. Бо  ле  сни  ке са ХЛЛ су одли-
ковали ни  ски обра  сци екс  пре  си  је CD20, CD22, CD79b и mIg 
(p<0,0001), те ви  сок ни  во екс  пре  си  је CD5 ан  ти  ге  на (p<0,05). 
Ко  ре  ла  ци  ја из  ме  ђу ко  нач  не ди  јаг  но  зе ЗБЋН и вред  но  сти 
ХЛЛ ско  ра по  ка  за  ла је да 97% бо  ле  сни  ка са ХЛЛ има ви  со  ке 
вред  но  сти ско  ра (5 или 4), док 96% бо  ле  сни  ка са оста  лим 
ЗБЋН има ни  же вред  но  сти ско  ра (0-3).
За  кљу  чак Ре  зул  та  ти ис  пи  ти  ва  ња су по  ка  за  ли да ти  пи  чан 
иму  но  фе  но  тип  ски про  фил ХЛЛ ће  ли  ја, ко  ји мо  же ди  фе-
рен  ци  ра  ти ХЛЛ од дру  гих ЗБЋН, пред  ста  вља ком  би  на  ци  ју 
сле  де  ћих мар  ке  ра: CD19+ CD20+ni zak CD22+ni zak CD5+vi sok CD23+ 
FMC7- CD79b+ni zak mIg+ni zak. Вред  но  сти ХЛЛ ско  ра од 5 или 4 
по  е  на ука  зу  ју на ди  јаг  но  зу ХЛЛ с ви  со  ком по  у  зда  но  шћу.
Кључ  не ре  чи: хро  нич  на лим  фо  цит  на ле  у  ке  ми  ја; иму  но  фе-
но  ти  пи  за  ци  ја; про  точ  на ци  то  ме  три  ја
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